Treatment

Cardiac Dimensions Included in the New 2021 ESC Guidelines for Heart Failure Management

Wednesday, September 22, 2021 - 2:00pm

KIRKLAND, Wash., Sept. 22, 2021 /PRNewswire/ --Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the mention of their Carillon Mitral Contour System in the 2021 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.

Key Points: 
  • KIRKLAND, Wash., Sept. 22, 2021 /PRNewswire/ --Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the mention of their Carillon Mitral Contour System in the 2021 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.
  • "I'm very pleased to see the Carillon Mitral Contour System mentioned in the 2021 ESC heart failure guidelines," commented Professor Dr. Horst Sievert,Director of the Cardiovascular Center in Frankfurt and the Director of Internal Medicine, Cardiology and Vascular Medicine of the Sankt-Katharinen-Hospital.
  • The guidelines are considered an important tool for the evaluation of heart failure patients with valvular heart disease in Europe.
  • Cardiac Dimensions is a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions.

Harmony Biosciences Announces Winners of Patients at the Heart and Progress at the Heart on Third Annual World Narcolepsy Day

Wednesday, September 22, 2021 - 1:05pm

Initiated in 2021, Progress at the Heart supports innovative programs that address disparities, injustice, and inequities in the rare disease and sleep disorder community.

Key Points: 
  • Initiated in 2021, Progress at the Heart supports innovative programs that address disparities, injustice, and inequities in the rare disease and sleep disorder community.
  • "We are so inspired by the diverse and inventive programs submitted for this year's Patients and Progress at the Heart programs," said Cate McCanless, SVP, Corporate Affairs and Public Policy.
  • The company chose to announce the winners on World Narcolepsy Day, a day dedicated to raising awareness for this sleep disorder globally.
  • The first Patients at the Heart program awarded $65,000 to four organizations, which was increased to $74,000 in 2020.

ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in September and October

Wednesday, September 22, 2021 - 1:00pm

Oryzon will present preliminary data from the ongoing collaboration with INGEMM in Phelan McDermid Syndrome (PMS) at the International Conference on Autism, ICA-2021, which will be held on September 23-24.

Key Points: 
  • Oryzon will present preliminary data from the ongoing collaboration with INGEMM in Phelan McDermid Syndrome (PMS) at the International Conference on Autism, ICA-2021, which will be held on September 23-24.
  • The communication entitled "Phenotype and Psychometric Characterization of Phelan McDermid Syndrome Patients" will be presented by Dr. Carlos Buesa, Oryzons CEO.
  • Executive directors of the company will attend the BIO Spain 2021 event, which will take place September 27-October 1.
  • The company will moderate a KOL panel discussion on precision medicine therapeutic approaches for CNS disorders and the potential of LSD1 inhibitors like vafidemstat.

Bright Minds Biosciences Provides Scientific Update

Wednesday, September 22, 2021 - 12:00pm

VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (Bright Minds, BMB or the Company) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today provided an update of significant scientific developments.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (Bright Minds, BMB or the Company) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today provided an update of significant scientific developments.
  • Over the past few months, we have dramatically improved BMBs competitive position with our therapeutic categories, as well as our broader capital markets strategy, stated Ian McDonald, CEO of Bright Minds.
  • This compound and its analogues were first invented by Bright Minds Chief Scientific Officer, Dr. Alan Kozikowski and Dr. Jianjun Cheng at the University of Illinois in Chicago.
  • Bright Minds Biosciences Inc. (the Company) has engagedIn-Site Communications Inc. (In-Site), previous service provider of the Company, for a 12-month term ending on March 30, 2022.

Businesses Prepare for New Era of Public Scrutiny as 83% Expect Investigations in Next 12 Months

Tuesday, September 21, 2021 - 7:30am

The survey of more than 2,800 executives from large public and private companies across G-20 nations found that 83% of those organizations either are being or expect to be investigated in the next 12 months.

Key Points: 
  • The survey of more than 2,800 executives from large public and private companies across G-20 nations found that 83% of those organizations either are being or expect to be investigated in the next 12 months.
  • The top three investigation worries are: business conduct and the treatment of customers, sustainability and ESG practices, and the relationship with public bodies and government contracts.
  • The services sector and financial sector were the most likely to report experiencing regulatory or political scrutiny over the past 12 months (23% each).
  • Class actions and mass consumer claims: 13% of respondents experienced these in the past 12 months, and the same percentage expect this to continue in the next 12 months.

New Study Finds Statistically Significantly Faster Healing Rates for Diabetic Wound Patients Treated with Kerecis Fish Skin

Monday, September 20, 2021 - 9:53pm

A study published in the peer-reviewed journal Wounds reports statistically significantly higher healing rates for diabetic foot ulcers (DFUs) treated with Kerecis Omega3 fish skin compared to DFUs treated with Fibrocol, a collagen-alginate dressing.

Key Points: 
  • A study published in the peer-reviewed journal Wounds reports statistically significantly higher healing rates for diabetic foot ulcers (DFUs) treated with Kerecis Omega3 fish skin compared to DFUs treated with Fibrocol, a collagen-alginate dressing.
  • Of the patients treated with the Kerecis product , 67% had healed after 12 weeks of treatment versus 32% in the control group.
  • These statistically significant results may give new hope to patients suffering from diabetic foot ulcers and other wounds, explained Kerecis founder and CEO Fertram Sigurjonsson.
  • The doctors in this study documented the healing efficacy of the Kerecis Omega3 fish-skin graft technology.

Olympus Selected To Exhibit iTind Device For BPH Treatment At Vizient Innovative Technology Exchange

Monday, September 20, 2021 - 3:17pm

CENTER VALLEY, Pa., Sept. 20, 2021 /PRNewswire/ -- Olympus has been selected to exhibit the iTind™ device, a temporarily implanted device for relief of enlarged prostate symptoms, at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation's largest member-driven health care performance improvement company, will hold the Exchange virtually September 21-23.

Key Points: 
  • CENTER VALLEY, Pa., Sept. 20, 2021 /PRNewswire/ -- Olympus has been selected to exhibit the iTind device, a temporarily implanted device for relief of enlarged prostate symptoms, at the Vizient Innovative Technology Exchange.
  • "Olympus is thrilled to bring the iTind device to the Vizient Innovative Technology Exchange," said Randy Clark, President of the Olympus Medical Systems Group.
  • The annual Innovative Technology Exchange is part of Vizient's Innovative Technology Program that includes product review of supplier-submitted technologies by member-led councils and task forces.
  • Since 2003, Vizient has received over 2,800 technology submissions as part of its Innovative Technology Program.

Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021 Financial Results

Monday, September 20, 2021 - 11:30am

WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today reported updates on its lead COVID-19 antibody program, ADG20, as well as recent business highlights and second quarter 2021 financial results.

Key Points: 
  • WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today reported updates on its lead COVID-19 antibody program, ADG20, as well as recent business highlights and second quarter 2021 financial results.
  • ADG20 is a highly differentiated antibody that we are advancing through pivotal trials for both the treatment and prevention of COVID-19.
  • Research & development expenses including in-process research and development for the second quarter of 2021 were $37.6 million.
  • Selling, general & administrative expenses for the second quarter of 2021 were $7.1 million.

Renowned Dental Sleep Medicine Specialist Dr. David Schwartz Joins Chicago-Area Dental Professionals

Thursday, September 16, 2021 - 2:15pm

CHICAGO, Sept. 16, 2021 /PRNewswire-PRWeb/ -- David Schwartz, DDS has joined the Dental Professionals team, bringing extensive experience and specialized training in sleep medicine to the practice.

Key Points: 
  • CHICAGO, Sept. 16, 2021 /PRNewswire-PRWeb/ -- David Schwartz, DDS has joined the Dental Professionals team, bringing extensive experience and specialized training in sleep medicine to the practice.
  • A practicing dentist since 1988, Dr. Schwartz is the current President of the American Academy of Dental Sleep Medicine (AADSM), the preeminent organization dedicated to this type of patient care.
  • Dental sleep medicine centers on oral appliance therapy (OAT), a clinically proven treatment for obstructive sleep apnea (OSA) and snoring.
  • Dr. Schwartz has authored numerous articles for professional publications including the Journal of Dental Sleep Medicine (JDSM), Journal of Clinical Sleep Medicine (JCSM) and Dental Sleep Practice (DSP) Magazine.

New Health Insurance Ratings Help Americans Find Quality Care During COVID and Opioid Crises

Thursday, September 16, 2021 - 2:00pm

WASHINGTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- New Health Plan Ratings from the National Committee for Quality Assurance (NCQA) give businesses and consumers who buy health insurance a user-friendly resource for choosing health plans.

Key Points: 
  • WASHINGTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- New Health Plan Ratings from the National Committee for Quality Assurance (NCQA) give businesses and consumers who buy health insurance a user-friendly resource for choosing health plans.
  • They also include assessments of care for people most at risk of dying from COVID and people at risk for opioid addiction.
  • Diabetes: Health Plan Ratings use five separate measures covering different aspects of care for people with diabetes.
  • NCQA's Health Plan Ratings are available at: reportcards.ncqa.org
    For information on how the ratings were calculated, see the NCQA ratings methodology: https://www.ncqa.org/hedis/reports-and-research/ncqas-health-plan-rating...
    FOR MORE INFORMATION OR TO ARRANGE AN INTERVIEW:
    NCQA is a private, nonprofit organization dedicated to improving health care quality.